Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Clinical trial NCT06042478 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06042478
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-15
- Primary completion
- 2025-09-17
- Enrollment
- 470
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.